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Abstract
Background: Various integrated care models have been used to improve treatment completion of medications for
chronic hepatitis B virus (HBV), chronic hepatitis C virus (HCV), Mycobacterium tuberculosis (TB), and Human
immunodeficiency virus (HIV) among people with substance use disorders (SUD). We have conducted a systematic
review to evaluate whether integrated models have impacts of the treatment of infectious diseases among
marginalized people with SUD.
Methods: We searched MEDLINE/PubMed (1946 to 2018, on July 26, 2018) and Embase (from 1974 to 2018, on July
26, 2018) for randomized controlled trials (RCTs) and cohort studies evaluating diverse integrated models’ effects on
sustained virological response (SVR), HIV suppression, HBV curation or suppression, completion of TB treatment
regimen among people with SUD. The included studies were assessed qualitatively.
Results: Altogether, 1640 studies, and references to 1135 related reviews and RCTs were considered, and only
seven RCTs and three cohort studies fulfilled the inclusion criteria. We identified nine integrated care models. Two
studies, one RCT and one cohort study, showed a significant effect of their integrated models. The RCT evaluated
psychosocial treatment, opioid agonist treatment (OAT) and directly observed TB treatment, and found a significant
increase in TB treatment completions among intervention group compared to control group (60% versus 13%, p <
0.01). The cohort study including OAT and TB treatments had an effect on TB treatment completion in hospitalized
patients (89% versus 73%, p = 0.03). Eight out of ten studies showed no significant effects of their integrated care
models on defined outcomes. One of which having included 363 participants in a RCT showed no effect on SVR
compared to the control group when the results adjusted for active substance use and alcohol dependence in a
post-hoc analysis (11% versus 7%, p = 0.49).
Conclusions: The findings indicate uncertainty on the effects of integrated care models’ on treatment for severe
infectious diseases among people with SUD. Some studies point toward that integrated models could improve care
of people with SUD, yet high-quality studies and preferably, sufficiently sized clinical trials are needed to conclude
on the degree of impact.
Keywords: Hepatitis C, Human immunodeficiency virus, Mycobacterium tuberculosis, Integrated care, Collaborative
care, Substance use disorder, Epidemiology, Systematic review
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: jorn.vold@uib.no
1Department of Addiction Medicine, Haukeland University Hospital, Bergen,
Norway
2Department of Global Public Health and Primary Care, University of Bergen,
Bergen, Norway
Full list of author information is available at the end of the article
Vold et al. BMC Infectious Diseases          (2019) 19:306 
https://doi.org/10.1186/s12879-019-3918-2
Background
Comorbid Hepatitis C virus (HCV) and hepatitis B virus
(HBV), human immunodeficiency virus (HIV), and
Mycobacterium tuberculosis (TB) infections are common
among people with substance use disorders (SUDs). Due
to a low level of attention to personal health care needs,
treatment of such severe infectious diseases may be diffi-
cult for people who inject drugs (PWID). Additionally,
PWID have a sustained high risk of transmitting these
severe infections [1–3]. Globally, 1.7 million PWID were
estimated to be HIV positive in 2016 [4]. Injection sub-
stance use is estimated to account for 1% of new HBV
infections and 23% of new HCV infections, respectively
[5]. A new global strategy to eliminate viral hepatitis that
aims to reduce HCV incidence by 90% and mortality by
65% by 2030 was endorsed by the World Health Assem-
bly in 2016 [5]. The World Health Organization (WHO)
and the United Nations Sustainable Development Goals
(SDGs) have also decided that the global strategies are
to end the acquired immune deficiency syndrome
(AIDS) epidemic by 2030 and the TB epidemic by 2035
[6–8].To succeed with such ambitious goals, high avail-
ability of coordinated care between medical treatment
and prevention, psychological care and social-related
services for people with SUD is pivotal. A systematic
search to identify efficacy of integrated care models on
treatment outcomes of severe infectious diseases among
people with SUD is required.
Integrated models may improve treatment completion
and adherence among people who often are marginal-
ized and hard to reach within current health services
systems [2, 3, 9, 10]. Comparing the efficacy of these
models is therefore of high importance. Different inte-
grated treatment models may improve the access for
completing treatment or achieving virus suppression
over time but most studies are small and not sufficiently
powered to quantify the effect size, and the patterns
have been slightly mixed [11–15].
Definitions of the concept of “integrated care” vary. In
the hospital setting, WHO defined integrated care as:
“an approach to strengthen people-centred health systems
through the promotion of the comprehensive delivery of
quality services across the life-course, designed according
to the multidimensional needs of the population and the
individual and delivered by a coordinated multidisciplin-
ary team of providers working across settings and levels
of care (…)” [16]. However, this definition is arguably too
broad and unspecific, hence, for the purpose of this
paper we have chosen to alter the definition of inte-
grated care to “comprehensive set of patient-centered
health services that involve the care of chronic infectious
disease as a part of coordinated services for people with
SUD.” Integrate care models and collaborative health
services may improve health outcomes to medical care,
as well as reduce the burden of disease among people
with physical and mental disorders [17], prevent severe
infectious diseases [18], improve engagement in TB ser-
vices [19], and increase patients adherence and staff sat-
isfaction [11]. Systematic reviews suggest that the
composition of the integrated models must be described
in more detail to identify effective integrated care
models that can be implemented in various settings [11,
18–20]. Previous systematic reviews have mostly identi-
fied descriptive reports or cohort studies, and only few
randomized controlled trials (RCTs) [11, 17, 21]. Also, a
number of these studies have methodological limitations
such as short follow up period, loss-to-follow-up rate on
more than 30%, unclear design and mixed outcome indi-
cators [11, 20]. In light of the SDGs and the World
Health Assembly global strategy for viral hepatitis, TB
and AIDS epidemics, a systematic review is imperative
to increase knowledge and understanding how to best
reach universal coverage of these severe infectious dis-
eases among people with SUD.
In this systematic review, we will examine the effect of
integrated health care for people with SUD receiving
treatment for HCV, HBV, HIV, and TB. Randomized
controlled trials and cohort studies presenting quantita-
tive comparative estimates will be compared to relevant
outcomes for each infectious disease. We hypothesized
that integrated care models might be useful to reach
marginalized low adherent people with SUD, although a
high risk of bias and loss-to-follow-up could underpow-
ered the results. This systematic review will summarize
the impact of integrated care models on the treatment of
severe infectious diseases among people with SUD and
will grade the evidence base on methodological quality.
Methods
Search strategy and selection criteria
We did a systematic search in MEDLINE/PubMed (1946
to 2018, on July 26, 2018) and Embase (from 1974 to
2018, on July 26, 2018) and Embase online search en-
gines. The search was built up of three main terms; 1)
infectious diseases (HCV, HBV, HIV, and TB), 2) sub-
stance use disorder and 3) integrated treatment. Sources
included MeSH-terms and all components in keywords,
title and abstract. The following search terms were
employed; 1) infectious diseases: “hepatitis C”, OR
“hepatitis B”, OR “human immunodeficiency virus”, OR
“tuberculosis”, 2) substance use disorder: “substance-re-
lated disorder” OR “narcotics agent” OR “withdrawal
syndrome” OR “substance abuse” OR “drug” in combin-
ation with “dependence”, “abuse”, “use”, “addict” OR
“disorder” and, 3) “delivery of health care, integrated”
OR “integrated health care system” (Additional files 1
and 2). The search strategy was developed in collabor-
ation with a certified university librarian.
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The three main terms were defined as follow:
1) Severe infectious diseases defined studies where the
study population was subject to treatment for HCV,
HIV, HBV, or TB.
2) Substance use disorder or behavior was defined
as people who use illegal or legal substances,
including alcohol, leading to dependency and
clinically significant impairment or distress, and
being in need of medical treatment in an
institution or outpatient clinic for at least one
SUD or the complication of the SUD.
3) Integrated treatment among marginalized people
with SUD was defined as “comprehensive set of
patient-centered health services that involve the
care of chronic infectious disease as a part of
coordinated services for people with SUD.”
WHO has recommended direct observatory therapy
(DOT) for TB infected to increase treatment completion
and decreased transmission rate [3]. However, for the
purpose of this systematic review, and in light of the
above definition of integrated care, studies employing
solely DOT that was not part of an integrated care
model were excluded.
In this paper, only randomized controlled trials and co-
hort studies were included. Cross-sectional studies, case
reports, commentaries, review papers, modeling analysis,
and reports without primary data were excluded, as stud-
ies lacking control groups. Studies were included for de-
tailed assessment if sub-groups of participants met or
were assumed to meet the criteria for substance use dis-
order. To further validate the literature search, and par-
ticularly to ensure that no papers that fulfilled the
inclusion criteria were overlooked, we also did an add-
itional search on MEDLINE/PubMed to screen for refer-
ences of relevant reviews, and RCTs. To ensure that all
integrated treatment models were taken into account, we
did a broad search, which included MESH-terms from
two of the three main terms; substance use disorder and
severe infectious diseases (Additional file 1). Then, the
relevant RCTs, as well as relevant references and
cross-references from the reviews, were selected in line
with the inclusion criteria. Studies not including patients
with SUD were excluded. The proportion of participants
with SUD is given in Table 1.
We employed the Newcastle-Ottawa quality assess-
ment scale (NOS) and the Consolidated Standards of
Reporting Trials (CONSORT) 2010 checklist for asses-
sing the quality of the studies. The NOS was graded in
eight methodological aspects, and a summary score for
selection, comparability, and outcome was ranked in
low, medium or high risk of low quality [22]. The CON-
SORT 2010 checklist was used to assess design, conduct,
analysis and interpretation, and the validity of the results
[23]. Two independent authors selected included studies,
and any discrepancies in the selection process were dis-
cussed within a review team of three members to
achieve consensus. Duplicate references were removed.
The search was last updated on July 26, 2018. The Pre-
ferred Reporting Items for Systematic reviews and
Meta-Analysis (PRISMA) criteria were followed
throughout the process (Additional file 3) [24].
Outcomes
Our outcomes were quantitative measures of treatment
effect on at least one of the infectious diseases tested in
an integrated care model. For HCV, sustained virological
response (SVR) at least 12 weeks after the end of treat-
ment was used as a primary outcome. For HIV care, we
used HIV viral suppression, and for TB, we evaluated
the completion of the recommended treatment regimen.
For HBV, we planned to use clearance of HBsAg or
HBeAg or suppression of HBV DNA as an indirect
measure of intervention effect as outcomes.
Data analysis
We were prevented from conducting quantitative
meta-analysis due to heterogeneity among study popula-
tions, incomparability among integrated care models, few
comparable studies, and different outcomes measures.
Consequently, all studies were assessed qualitatively. All
relevant quantitative outcomes of interest were assessed
where appropriate. Odds ratio (OR) or relative risk (RR)
with 95% confidence intervals, probability measures (p–
values), and descriptive analyses of outcomes of interest
were referred if it was stated in the articles. For compari-
son, we chose to categorize the included studies into two
groups based on whether the participants’ received opioid
agonist treatment (OAT) or not.
OAT as a multidisciplinary treatment approach has
shown to improve HIV treatment and care among
PWID [25], and might also serve to influence the effect
of integrated care models. Unfortunately, comparability
analyses between the groups were impossible due to in-
comparable studies, and different study populations. In
addition, participants with all dependencies were in-
cluded independent of groups.
Results
Altogether, 1640 studies were identified in Embase and
PubMed, and references to 1135 related reviews and
RCTs were considered (Additional file 2). However, only
three studies on HCV [13, 26, 27], five on HIV [14, 15,
28–30], and two on TB [31, 32] fulfilled the inclusion
criteria (Fig. 1). Nine integrated models in ten studies
were identified, whereas two studies assessed a similar
integrated model. We did not identify any relevant
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studies on hepatitis B. The CONSORT 2010 checklist or
the NOS were employed for assessing the quality of the
included studies (Additional files 4 and 5). All included
studies assessed integrated models of care when partici-
pants underwent medical treatment for HIV, HCV or
TB. Nine studies recruited patients from either a pri-
mary health care centers for people with SUD, OAT out-
patient clinics or specialist outpatient clinics for HIV or
HCV infected [13–15, 26–30, 32]. One study evaluated
TB treatment among hospitalized patients [31]. Four
studies also included people without SUD [26–29]. Six
out of ten studies were considered to have a
loss-to-follow-up rate on more than 30% (Table 2) [13,
15, 26, 27, 29, 32].
Different integrated care models were identified. All
studies assessed integrated care in multidisciplinary teams
or collaborative care teams. Three studies evaluated vari-
ous psychosocial interventions integrated with treatment
of an infectious disease in an OAT program delivery by
DOT [13, 31, 32]. Seven studies evaluated the efficacy of
brief psychological interventions, regular telephone calls,
or social and mental health services in collaboration with
other health professionals [14, 15, 26, 28–30, 33].
Nine integrated care models were identified, which were
subsequently divided into two groups; (1) integrated care
with OAT; and (2) integrated care without OAT.
Integrated care and opioid agonist treatment
Out of the six studies on integrated care with OAT [13–
15, 30–32], only two studies found an effect of the inte-
grated care intervention [31, 32]. Hospitalized patients in-
fected with TB receiving OAT in an integrated care setting
showed a significant improvement on TB treatment com-
pletion (90% versus 74%, p = 0.03) and the adherence to
TB medication (97% versus 86%; p < 0.01) after controlling
for death and dropouts [31]. Additionally, Batki et al.
(2002) found a significant effect on HIV suppression when
integrating directly administrated OAT and antiretroviral
therapy (ART) against HIV, counseling, psychiatric treat-
ment and social works were compared to standard routine
care in an outpatient clinic in people with SUD (60% ver-
sus 13%; p < 0.01) [32]. The remaining four studies
showed no significant effect of integrated care on HIV
suppression or achievement of HCV SVR when OAT and
antiviral therapy against HIV or HCV were integrated at
outpatient clinics [13–15, 30].
In the TB study that showed significant effects, inte-
grated care was conducted among hospitalized TB in-
fected [31]. The results indicated that OAT increased
the adherence and completion to treatment in a pro-
tected environment. The intervention group was re-
cruited from three districts among patients receiving
OAT and outpatients TB treatment. Similarity, the
Fig. 1 Flow diagram
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control group was recruited from three districts where
people with opioid use disorder were undergoing TB
treatment, however, without OAT. Fifty-seven partici-
pants were recruited to integrated treatment compared
to 53 participants in the control group. DOT was used
for TB treatment, and this was integrated with OAT.
Basic characteristics were entirely different between the
intervention group and the control group, indicating
that the study was underpowered or had biases in the
randomization. There were differences in the proportion
of people above 36 years of age (the intervention group:
61%, the control group: 36%, p < 0.01), use of amphet-
amine in the last 30 days (the intervention group: 5%,
the control group: 25%, p < 0.01), and lifetime duration
of substances used more than 17 years (the intervention
group: 65%, the control group: 32%, p < 0.01).
Batki et al. (2002) conducted a randomized controlled
trial showing a significant effect on preventive TB treat-
ment completion. TB and OAT treatments were inte-
grated into DOT models with or without psychosocial
interventions with 6 months follow-up. TB treatment
completion was defined as 80% or greater of all doses
taken. Seventy-seven percent (n = 27) of participants
randomized into the DOT model without psychosocial
interventions achieved treatment completion compared
to 60% (n = 22) of participants randomized into DOT
model with integrated psychosocial interventions. In the
control group, 14% (n = 5) completed the TB treatment.
The two OAT treatment groups had significantly higher
TB treatment completion rate compared to the control
group (p < 0.01). However, there were no significant dif-
ferences between the OAT treatment groups in the rate
of TB completion. Characteristics of participants at the
baseline were equal between the groups, except age (p =
0.047), and scores assessing the severity of problems in
individuals with SUD (The Addiction Severity Index psy-
chiatric composite score (p = 0.027) and the severity of
depression (Beck Depression Inventory scores (p =
0.022)). Unfortunately, the loss-to-follow-up rate was
52%. The results may indicate a limited effect of psycho-
social interventions add to directly administrated ther-
apy to increase treatment completion of TB.
Moreover, a RCT study evaluated a clinic-based inte-
grated treatment model in a HIV clinic [30]. All included
participants received antiretroviral therapy in the clinic
and had an opioid use disorder. The study evaluated the
effect of assessment and initiation of OAT in the HIV
clinic on HIV suppression. All opioid addicted who
qualified to induct OAT were randomized. Participants
randomly assigned to the control group were encour-
aged to be referred to the opioid treatment program.
Participants randomized to the intervention delivered
their OAT medications in the HIV clinic during 12
months follow-up. After 12 months, changes from
baseline of HIV RNA and CD4 cell counts did not sig-
nificantly differ between the groups (p = 0.31 and p =
0.16, respectively). However, the clinic-based interven-
tion group had higher participation in OAT over 12
months of follow-up. This study enrolled only 78% of
the estimated sample size, which is a limitation of the
study’s validity. Also, a relatively high loss-to-follow-up
rate on 17% and inclusion of only one single-center im-
pairs the generality of the study’s results.
Two more studies evaluated integrated HIV care [14,
15]. HIV suppression and self-reported adherence to ART
were evaluated in a non-randomized cohort study that
compared integrated HIV treatment in an outpatient
clinic among OAT patients to providing ART in an HIV
outpatient clinic to patients with SUD [14]. Thirty-five pa-
tients were recruited to receive integrated care, and 175
patients recruited to the control group. The virological re-
sponse was defined as HIV suppression below 400 copies/
mL, and the immunological response as CD4 cell count
above 200 cells/μL after at least 6 months. Among pa-
tients enrolled in OAT 97% achieved virological response
compared to 90% in the control group (p = 0.27). Approxi-
mately 69% had an immunological response compared
with 57% in the control group (p = 0.93). No significant
differences were established among self-reported adher-
ence and virological and immunological response between
these groups. Participants in the intervention group re-
ceived ART weekly and the self-reported number of medi-
cations taken the last week was reported. Basic
characteristics at baseline and loss-to-follow-up were not
significantly different between the groups.
Another randomized controlled trial compared an inte-
grated intervention on HIV suppression among people with
opioid use disorder to standard treatment [15, 34]. Integrated
care was psychosocial intervention conducted by nurses.
Twenty-two participants were randomized to integrated care
and 25 participants received standard care. After the partici-
pants were included, and 2 weeks before randomization, all
participants were stabilized on buprenorphine-naloxone. The
outcome was changes in viral suppression 12weeks after the
intervention was initiated. After 12weeks the number of
HIV copies decreased from 58% at baseline to 43% at 12
week in the intervention group, and from 56 to 35% in the
control group, p= 0.84 and p= 0.27, respectively, probably
due to low sample size. The integrated psychosocial inter-
ventions were completed by a mean of 3.0 (standard devi-
ation (SD) = 1.2) sessions per months in 3 months with a
mean session length of 47min (SD= 5.3). All participants
provided consultation with a physician bi-weekly. The adher-
ence to ART and the buprenorphine-naloxone medications
was monitored by a medical event monitoring system,
micro-electro-mechanical-system (MEMS® –cap). Baseline
characteristics were equal in both groups, except years of
HIV infection among participants (the intervention group:
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8.7 (SD= 6.5), the control group: 15.4 (SD= 4.6), p < 0.01).
The loss-to-follow-up was 30%. Some participants received
the HIV medication in a different clinical site than that
buprenorphine-naloxone was provided, representing a high
risk of bias.
A small randomized controlled trial on HCV evaluated
integrated care that included modified DOT compared to
self-administrated HCV treatment among patients in OAT
[13]. Twenty-one participants were recruited, 12 and nine
were randomized to the intervention group and the control
group, respectively. The primary outcome was SVR. The
modified DOT models were organized in such a way that
the hepatitis C medications and the OAT were taken under
observation at the same time. Patients got an injection of
peg-Interferon weekly and received the morning doses of
Ribavirin together with an opioid agonist medicine. To
monitor adherence, participants received a take-home
evening doses in MEMS®-cap. Six out of ten and one out of
four obtained SVR in the intervention group and the con-
trol group, respectively. The loss-to-follow-up was 67%, out
of a small initial population. In addition to a prone to selec-
tion bias, the results were underpowered to evaluate the ef-
fect of the intervention in this study. Small sample size,
selection bias, and inconclusive outcomes lead to a careful
assessment of the results.
Integrated care without opioid agonist treatment
We identified four studies with integrated care without
OAT [26–29]. Substance use disorders were reported
from 46 to 100% of the participants in the included
studies (Table 1). Two of four studies used the terms
“substance use disorder”, and “substance use”, however;
the studies did not notice the type of substance depend-
encies [26, 27]. These two studies reported that heroin
and cocaine were used in 87 and 13%, and 50 and 52%
of the participants, respectively [28, 29]. One study
found a significant effect of brief psychological interven-
tion care having 29 (16%) participants in the interven-
tion group and 14 (8%) participants in the control group
that achieved SVR (OR = 2.26, 95% CI, 1.15–4.44, p =
0.02) on patients that were screened and that tested
positive for depression, post-traumatic stress disorder
(PTSD) and/or substance use disorder. A post-hoc ana-
lysis comparing people with and without SUD did not
find a significant effect on SVR, having 20 (11%) in the
intervention group and 14 (7%) in the control group that
achieved SVR, p = 0.49) [27]. Integrated care seems to
improve SVR, but as this study was not powered for
subgroup analysis of SUD patients the results are not
significant and may also have been achieved by change.
In contrast, three studies failed to show any effect at all
[26, 28, 29].
A RCT in a HIV primary care outpatient clinic compared
an integrated care (n = 65) versus standard care (n = 71) to
HIV infected [29]. The intervention consisted of six
one-hour group session, twice monthly, where treatment
barriers, ART adherence, and HIV stigma barriers such as a
sexual and romantic relationship, substance use and mental
health problems were discussed. The control group re-
ceived standard care and was given social and mental
health referrals. The primary outcome was suppression of
HIV RNA at baseline, at 3 and 6 months. A post-hoc ana-
lysis revealed no significant differences on HIV suppression
between baseline, compared to 3 months and 6 months fol-
low up after treatment initiation. Baseline characteristics
were similar in both groups. Only half of the study popula-
tion had a heavy lifetime substance use of either alcohol,
cocaine or heroin. Only 59% follow-up at baseline, 65% at 3
months, and 61% at 6 months, reported taking 95% or
more of their prescribed medications.
Furthermore, a cohort study evaluated HIV suppres-
sion between HIV infected transmitted through sub-
stance use (intervention) or intercourse (control)
followed up with blood samples at baseline, weeks 48
and 96 [28]. Active and recent people with SUD were re-
cruited to the integrated care group where they received
medical care, drug use disorder treatment, and psycho-
social support. People transmitted through intercourse
were received standard medical support at the infectious
diseases unit of the reference hospital. The primary out-
come of the study was time to loss of virological re-
sponse defined as HIV RNA above 500 copies/mL after
getting HIV RNA below 50 copies/mL, or not getting an
HIV RNA below 50 copies/mL after week 24.
Seventy-one people transmitted through substance use
and 48 matched infected through sexual transmission
were included. HIV suppression was measured by HIV
RNA. At week 48, 93% (95% CI, 87 - 99%) of the inter-
vention group and 94% (95% CI, 84 - 100%) of the con-
trol group achieved virus suppression, respectively. At
week 96, 87% (95% CI, 79 - 95%) and 88% (95% CI, 78 -
97%) achieved virus suppression, respectively. No signifi-
cant differences between substance users and people
transmitted through intercourse were found at week 48
(p = 0.13) and week 96 (p = 0.24) compared to baseline
Kaplan-Meier estimates (log-rank test) of time to loss of
virological response and was not significantly different
between the groups (p = 0.97). Basic characteristics were
entirely different such as CD4 cell count (209 cells/μL,
range, 3–427 cells/μL versus 294 cells/μL, range, 29–465
cells/μL, p < 0.01) and psychiatric comorbidities (person-
ality disorder, depression, psychotic disorder, and bipolar
disorder, p < 0.01). Loss-to-follow-up was indifferent in the
intervention versus control groups, 13 and 8% (p = 0.18),
respectively.
Two studies evaluated integrated versus standard HCV
care in a hepatitis C medical center with HCV infected
veterans with psychiatric diseases or SUD [26, 27]. The
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primary outcome was SVR. Participants randomized to in-
tegrated care were seen by mental health providers (one
marriage and family therapist and two psychologists) who
were educated in cognitive behavioral therapy (CBT) and
motivational interviewing (MI). The participants received
regular individual appointments, briefing before and
under the antiviral treatment. The participants were con-
tacted by the provider monthly and more frequently if
they had side effects and worsening of psychiatric illness
and substance use disorder during treatment.
In the first randomized HCV cohort study, 363 partici-
pants were randomized in total (n = 182 for integrated
care and n = 181for standard care) [27]. Of those, 58 in
the intervention group and 34 in the standard care
group initiated treatment, respectively. In the interven-
tion group, 14 participants achieved SVR (OR 2.26, 95%
CI, 1.15–4.44, p = 0.02). To compare people with and
without SUD, a post-hoc analysis on 20 (11%) in the
intervention group and 14 (7%) in the control group was
done. No significant effect on SVR was found between
these groups, p = 0.49, but this post-hoc analysis was not
powered for this subgroup analysis and the results could
be random. Baseline characteristics were equal. Sub-
stance use disorder was detected in 66% of the partici-
pants, and 47% had active substance use. People
loss-to-follow-up was 53%.
In the second randomized HCV cohort study, altogether
79 participants were recruited (n = 40 in the intervention
group and n = 39 in the control group) [26]. Of those, only
18 and 9 initiated treatment, and 12 and 8 participants
achieved SVR (p = 0.23), respectively. SVR was not signifi-
cantly different between these two groups. Both studies
used a combination of interferon-based treatment and
direct-acting antivirals (DAA). Baseline characteristics
were equal, except age (intervention group age = 54.0 (SD
= 8.7) and the control group age = 57.4 (SD = 7.7), p =
0.01). Substance use disorder was identified in only 47% of
the participants, and in 32% of those using substances ac-
tively. Loss-to-follow-up was again considerable at 59.3%.
Overall, all the included studies, with or without OAT as
a part of integrated care model had a high loss-to-follow-up
rate [13, 15, 26, 27, 32], unclear description of the inte-
grated intervention [14, 31], or the primary outcome was
based on self-reporting of adherence to medication and
substance use [14, 15]. Five studies had a loss-to-follow rate
of more than 30% [13, 15, 26, 27, 32] and for one study the
quantitative rate was not given [14]. In this review, one out
of four studies without OAT showed significant effects of
the interventions. However, this study also included people
without SUD [27]. When the results were adjusted for
people with SUD or alcohol dependence in a post-hoc ana-
lysis, no significant effect on the intervention was found. In
total, three out of the ten included studies used psycho-
logical interventions as a major part of the study
intervention [15, 26, 27]; none of which measured a signifi-
cant effect on people with SUD compared to the control
groups.
Discussion
We assessed the impact of integrated care models
among patients with SUD and severe infectious diseases.
Many relevant studies were excluded due to a low level
of collaborative care involvement, or measurements of
outcomes that were not relevant to our review. Overall,
most of the included studies were considered to have a
high risk of biases and both the results and methodology
were heterogeneous. A recurrent finding was a high
loss-to-follow-up rate, unclear description of the inter-
ventions, and underpowered studies. Moreover, differ-
ences in potential confounders between groups in
cohort studies including age, proportion of homeless-
ness, proportion of people who inject drugs, employ-
ment status, level of education, and severe psychiatric
disorders to name but a few. Potential confounders may
further bias the interpretation of the results.
The impact of integrated treatment among people with
SUD on viral suppression, HCV SVR and TB treatment
completion is uncertain according to our findings. In
our review, a quantitative meta-analysis has not been
performed due to limited comparable studies of high
quality. Only two studies found an effect of integrated
treatment. One of them found an effect of integrated
OAT given to hospitalized TB-infected patients on treat-
ment completion and medication adherence [31]. The
second one found an effect on collaborative care when
antivirals and OAT were given as DOT with or without
psychosocial interventions [32]. Other OAT integrated
models had uncertain effects. A meta-analysis published
in 2016 suggested that OAT was associated with an in-
crease in ART coverage and adherence to ART, and lim-
ited evidence for OAT decreasing mortality for PWID
on ART [25]. A similar impact of OAT on adherence to
hepatitis C and TB treatment has not been shown. How-
ever, Altice, FL, et al. (2011) evaluated in a multicenter
study an integrated OAT model in a HIV clinical care
settings, and found no association between integrated
OAT and viral suppression [35]. An important limitation
was the lack of a control group, which was the reason
why we did not include it in our review.
The adherence to medical treatment in an integrated
care model may be influenced by many other factors af-
fecting the patient’s ability to follow up treatment as pre-
scribed. Personal characteristics such as age, gender,
mobility, lack of motivation, somatic and psychiatric co-
morbidities, and previous experiences, are some of the
examples [36]. OAT as a part of an integrated care
model may have an impact on patient’s ability and inter-
est to follow up medical treatment. Comprehensively
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integrated care models, including OAT, may consist of
different medical, psychological and social approaches
influencing the effect on integrated care. The efficacy of
these approaches is uncertain and must be explored
more in detail in the future RCTs with sufficient power
in order to study more precisely the effectiveness of inte-
grated care and how it influences adherence and treat-
ment completion.
Three studies that included psychological intervention by
clinical psychologists or psychosocial intervention by nurses
under clinical guidance of a clinical psychologist as a part
of the integrated care were included in this literature re-
view. The effects of psychological intervention on our out-
comes are too weak to measure quantitatively. A previous
systematic review has measured the effects of psychosocial
interventions on people with SUD and severe mental ill-
nesses quantitatively independently of infectious disease
treatment [21]. Different psychosocial interventions were
assessed, including MI, CBT, and skills training. Overall,
the results were affected by low to very low rate of evidence
and unclear risk of bias. Based on 32 RCTs, no compelling
evidence to reduce substance use or improve mental state
in patients with severe mental illnesses was found. How-
ever, a systematic review and meta-analysis on collaborative
care models have shown to be useful to enhance mental
and physical outcomes among patients with mental disor-
ders [17]. Three studies included people with SUD, but no
intervention was qualified to be included as collaborative
care models. The main focus of the studies was integrating
or coordinating primary care with an ongoing psychosocial
oriented substance use treatment program. It is uncertain
whether a psychological intervention that is used in the
treatment of severe infectious diseases among patients with
SUDs improves the viral suppression or treatment comple-
tion. Again, there is an urgent need for high-quality RCTs
with a detailed description and definition of integrated
treatment models effect on quantitatively outcomes mea-
surements, and where the risk of bias is reduced.
Three of the included studies in this systematic review
evaluated DOT as a tool to increase treatment comple-
tion [13, 31, 32]. Generally, DOT did not meet our def-
inition of integrated care but was included as one of
several approaches on three of the integrated care
models. In two of the cases, it is uncertain how much
the DOT element per se affected the results. In our re-
view, two studies including DOT in an integrated setting
showed a significant effect on TB treatment completion.
DOT is a controversial method due to challenges with
patient’s autonomy and could leave the patients as a pas-
sive recipient of therapy [37]. However, DOT is a part of
the WHO strategy, “Directly Observed Therapy Short
course,” whose proposing to increase the completion of
the TB treatment, and reduce contamination [38]. DOT
has been less commonly implemented in HIV, HBV, and
HCV strategies due to lack of compelling evidence in
support for this treatment. DOT has been evaluated in a
systematic Cochrane review as a treatment modality to
affect treatment completion on TB infected [12]. Inter-
estingly, DOT was compared to self-administration of
therapy and compared between PWIDs receiving TB
prophylaxis as DOT to standard care. DOT compared to
self-administration showed a similar pattern to comple-
tion of TB cure, but stratified analyses on people with
SUD or marginalized people were not surveyed. Similar-
ity, one study that was included in the Cochrane review
compared DOT to standard care among PWIDs [39].
Three hundred PWID received TB prophylaxis delivered
by DOT or no observation. Treatment completion was
not significantly different between DOT compared to
self-administration.
The etiological treatment for hepatitis C and HIV have
improved significantly in the last decade. New DAAs
against chronic hepatitis C are better tolerated and have
a better efficacy than traditional interferon-based treat-
ment, and could therefore markedly reduce the global
chronic hepatitis C epidemic [5, 40]. A high cost has
limited the distribution to not only low- and
middle-income countries, but also high income coun-
tries such as Norway [5, 41]. From February 1, 2018,
however, all chronic HCV patients in Norway have given
an opportunity to receive treatment with DAAs regard-
less of genotype and liver fibrosis level. Among recent
advances in ART against HIV are increased potency
making single tablet treatment feasible, better tolerance,
and improved viral suppression [42, 43]. In our review,
DAAs were not tested systematically in a separate study,
and stratified analysis based on this item is not surveyed.
However, Norton et al. (2017) have evaluated new DAAs
among people who actively use drugs and received OAT
in an integrated model [44]. The results of this
non-controlled study showed that substance use and
OAT are independently associated to a high SVR rate (>
90, 95% CI: 42 - 99%) when DAAs are given in a coordi-
nated service. Due to the small sample size and lack of
control group, the results are uncertain and must be
confirmed in high-quality studies. Further integrated
care models and new antivirals may contribute to ensur-
ing better availability and treatment completion.
The chief limitation of this review is the lack of rele-
vant studies, which fulfilled our inclusion criteria. Thus,
we were unable to conduct a meta-analysis. Heterogen-
eity of these studies and methodological shortcomings
also made it more challenging to synthesize clear pat-
terns of evidence. In an attempt to minimize methodo-
logical shortcomings, we opted a strict definition for
inclusion. A wider definition of search strategy will in-
clude a wider range of approaches but also approaches
where the health care is not substantially different from
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more traditional given health care. This could make it
more difficult to assess meaningful effects from compar-
isons. Thus, trying to balance these aspects we have
opted for slightly narrower definition of integrated care
than Haldane et al. (2017) have used in a review focusing
on HIV, substance use and service integration [11].
Nevertheless, integrated treatment, as well as substance
use disorder, are frequently used terms that are used
with a range of definitions. Several synonyms and terms
applied in the literature, makes it challenging to create a
search strategy that identify all terms and synonyms
used without using extremely broad search strategies.
The additional pragmatic search on references and
cross-references of relevant reviews, and RCTs, includ-
ing two more relevant studies, is a high proportion of
studies compared to those identified in the main search.
Still, we cannot rule out that some studies lack. Inte-
grated treatment can be seen as a continuous scale from
studies comparing models with limited differences from
conventional strategies to the studies with pronounced
differences. Choosing where to set the exact threshold of
the “borderline” studies with limited differences can be
difficult. However, the studies with limited differences
between more conventional and integrated are unlikely
to inform as much on the effects of integrated treatment
as studies with more pronounced differences.
Furthermore, one could argue that RCTs and cohort
studies measuring other outcomes than HIV viral sup-
pression, HCV SVR and TB treatment completions
should be included for a wider range of integrated
models. On the other hand, subjective outcomes such as
self-reported adherence to treatment approaches, change
of substance use, and as well as self-reported change of
risk behavior are substantiality uncertain outcomes,
which are affected by weaknesses. These risks are poten-
tially more pronounced among people who actively use
drugs than others due to the drugs effect on cognitive
functions [45]. Due to these argumentations, in this re-
view we want to identify all high-quality studies with
hard outcomes on at least one of the infectious diseases.
Finally, one could argue that studies assessing
non-SUD patients groups could be included in the as-
sessment, but that could further add to the heterogen-
eity, and it would be uncertain to what extent the
findings could be generalized to people with SUD.
Conclusion
This systematic review identified various integrated care
models to reach and treat a group of marginalized patients
with substance use disorders and severe infectious dis-
eases. Even most of the included studies had high risks of
biases and presented uncertain results. Hospitalized pa-
tients, who received integrated treatment for opioid use
disorder during TB treatment, seemed to improve
medication adherence and treatment completion. Add-
itionally, integrated psychosocial interventions and dir-
ectly observed OAT together with ART have been shown
to improve the HIV viral suppression. For chronic HCV
infected, no studies yet have shown compelling evidence
of its benefits.
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